ACM
APLS

Asymmetry Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Asymmetry Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$6.59M Buy
+139,445
New +$5.49M 3.5% 14
2020
Q1 		– Sell
-21,380
Closed -$655K – 31
2019
Q4 		$655K Buy
+21,380
New +$592K 1.17% 33

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Asymmetry Capital Management's APLS Position: Q4 2021 in Review

Asymmetry Capital Management opened a new position in Apellis Pharmaceuticals (APLS) in Q4 2021: 139,445 shares worth $6.59M. The stake represents 3.5% of the portfolio and ranks #14 among its holdings. This is a return to the name: Asymmetry Capital Management previously reported a position in APLS as recently as Q4 2019.

Asymmetry Capital Management first reported a position in APLS in Q4 2019 and has held it in 2 quarters since. 187 funds tracked by Wall St. Rank hold APLS as of Q4 2021.

  • Asymmetry Capital Management held 139,445 shares of Apellis Pharmaceuticals worth $6.59M as of Q4 2021.
  • Apellis Pharmaceuticals was a new Asymmetry Capital Management position in Q4 2021.
  • Apellis Pharmaceuticals made up 3.5% of Asymmetry Capital Management's portfolio in Q4 2021, its #14 holding.
  • Asymmetry Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2019 and has held it in 2 quarters since.
  • 187 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2021.

Based on Asymmetry Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.